Skip to main content

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Annual Virtual Healthcare Conference.

The fireside chat will take place on Tuesday, April 8, 2025, at 12:45 PM ET - Track 1.

The fireside chats can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of each presentation.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau® and Nuceiva®, are registered trademarks and Evolysse is a trademark of Evolus, Inc.

Contacts

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: ir@evolus.com



Media:

Email: media@evolus.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.15
+3.29 (1.61%)
AAPL  262.46
+1.88 (0.72%)
AMD  199.72
-3.65 (-1.79%)
BAC  52.55
-0.22 (-0.41%)
GOOG  314.74
+11.18 (3.68%)
META  655.18
+10.40 (1.61%)
MSFT  397.03
-1.43 (-0.36%)
NVDA  188.27
+0.37 (0.20%)
ORCL  148.99
-7.55 (-4.83%)
TSLA  407.72
-3.99 (-0.97%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.